FindTrial
Sign In

AZD9150

DRUG7 trials

Sponsors

AstraZeneca, National Cancer Institute (NCI), MedImmune LLC, Acerta Pharma BV

Conditions

Advanced Adult Hepatocellular CarcinomaAdvanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and NeckAdvanced Solid TumoursAscitesDLBCLDiffuse Large B Cell LymphomaDiffuse Large B-Cell LymphomaGastrointestinal Cancer

Phase 1

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
CompletedNCT01839604
AstraZenecaAdvanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
Start: 2013-05-31End: 2015-02-28Updated: 2017-03-06
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
CompletedNCT02499328
AstraZenecaAdvanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Start: 2015-08-06End: 2025-10-08Updated: 2026-02-11
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Active, not recruitingNCT02546661
AstraZenecaMuscle Invasive Bladder Cancer
Start: 2016-12-28End: 2026-01-30Updated: 2025-12-29
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
CompletedNCT02549651
MedImmune LLCDiffuse Large B-Cell Lymphoma
Start: 2016-07-13End: 2019-02-04Updated: 2019-02-27
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
CompletedNCT03421353
AstraZenecaAdvanced Solid Tumours
Start: 2018-02-07End: 2024-03-28Updated: 2024-08-21
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
CompletedNCT03527147
Acerta Pharma BVDiffuse Large B Cell Lymphoma, DLBCL, NHL +1
Start: 2018-06-19End: 2021-03-31Updated: 2022-08-15

Phase 2

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
TerminatedNCT02417753
National Cancer Institute (NCI)Ascites, Gastrointestinal Cancer, Gastrointestinal Neoplasms +2
Start: 2015-04-03End: 2016-04-07Updated: 2017-05-15

Related Papers

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
BMJ Oncology2024-07-015 citations
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
2024-02-0738 citations
Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
Blood2022-11-155 citations
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study
BMJ Open2022-10-0131 citations
A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood2021-11-052 citations
Abstract 390: Identification of a novel immunosuppressive myeloid gene expression signature for clinical biomarker development
Cancer Research2021-07-01
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
2021-05-2445 citations
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
2021-05-0384 citations
Abstract LB-105: Plasma exposure-target engagement biomarker analysis for danvatirsen after multiple dosing schedules and route of administrations in patients with advanced solid tumors
Cancer Research2020-08-15
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Blood2019-11-136 citations
Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch.
2019-01-1910 citations
A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
Annals of Oncology2018-10-0145 citations
Abstract CT103: Rationale for flat dosing of AZD9150 by population pharmacokinetic analysis
Cancer Research2018-07-01
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
2017-01-1049 citations
BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.
Journal of Clinical Oncology2016-05-209 citations